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Abstract 
 
Inﬂammation and cancer are related pathologies acting synergistically to promote 
tumor progression. In both, hematogenous metastasis and inﬂammation, P-selectin 
participates in interactions involving tumor cells, platelets, leukocytes and endothelium. 
Heparin has been shown to inhibit P-selectin and as a consequence it blunts metastasis 
and inﬂammation. Some heparin analogs obtained from marine invertebrates are P-
selectin inhibitors and do not induce bleeding effects. The present work focuses on the 
P-selectin blocking activity of a unique heparan sulfate (HS) from the bivalve mollusk 
Nodipecten nodosus. Initially, we showed that the mollusk HS inhibited LS180 colon 
carcinoma cell adhesion to immobilized P-selectin in a dose-dependent manner. In 
addition, we demonstrated that this glycan attenuates leukocyte rolling on activated 
endothelium and inﬂammatory cell recruitment in thioglycollate-induced peritonitis in 
mice. Biochemical analysis indicated that the invertebrate glycan also inhibits 
heparanase, a key player in cell invasion and metastasis. Experimental metastasis of 
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Lewis lung carcinoma cells was drastically attenuated by the mollusk HS through a 
mechanism involving inhibition of platelet–tumor-cell complex formation in blood 
vessels. These data suggest that the mollusk HS is a potential alternative to heparin for 
inhibiting P-selectin-mediated events such as metastasis and inﬂammatory cell 
recruitment. 
 
 
 
Introduction 
 The relationship between cancer and inflammation has been increasingly reported 
during the last decade [1]. However the connection between these two pathologies was first 
suggested about 150 years ago [2]. Whereas acute inflammation is part of the organism 
defense response, chronic inflammation can lead to cancer. Indeed, patients with ulcerative 
colitis and Crohn’s disease, have higher risk to develop colorectal cancer [3]. On the other 
hand, during hematogenous metastasis, natural killer cells can attack tumor cells, decreasing 
the metastasis rate. Thus, the function of leukocytes in tumor biology is complex [4] and 
represents an attractive research.  
 Hematogenous metastasis and inflammatory cell recruitment strongly depend on 
selectin function. P-selectin is a family member of glycan-recognizing adhesion molecules. In 
endothelial cells, P-selectin is stored in Weibel–Palade bodies, whereas in platelets, it occurs 
in α-granules. P-selectin is readily exposed at the surface of platelets upon activation, 
mediating its interaction with leukocytes and endothelial cells [10].  Tumor cells are 
characterized by aberrant glycosylation patterns [11, 12], including the over-expression of 
highly branched or sialylated oligosaccharides, especially fucosylated glycans, such as sialyl-
LewisX and sialyl-Lewisa. These glycans are ligands for selectins and their presence is related 
to poor prognosis due to increased metastatic disease [13, 14].   
The metastatic process is comprised of several steps that include degradation of 
basement membrane, entry of cancer cell into the bloodstream, evasion of innate immune 
surveillance, adhesion to the vascular endothelium of secondary sites with subsequent 
extravasation and colonization. Once in the bloodstream, cancer cells are covered by 
platelets, in a P-selectin-dependent process, forming a natural barrier against immune system 
cells [6]. On the other hand, leukocytes recruitment during inflammation is mediated by P- 
and L-selectins. These adhesion molecules are involved in the first steps of cellular 
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recruitment by decreasing the rolling velocities of leukocytes, contributing to their adhesion 
and arrest at sites of inﬂammation. 
 Cancer patients have high-risk of developing thromboembolic disease and therefore, 
heparin has been used as a prophylactic therapeutic agent. Retrospective analysis of patients 
under heparin therapy revealed a better prognosis of the malignant disease, which has not 
been associated with the anticoagulant effect of the drug [15, 16]. Several studies aimed to 
investigate the anti-cancer effect of heparin revealed that it attenuates experimental 
metastasis in animals [9], mainly by binding to P-selectin and decreasing the interaction 
between tumor cells and platelets. Additionally, heparin can also attenuate metastasis by 
inhibition of heparanase [17], the only known mammalian endoglycosidase that cleaves 
heparan sulfate and is over-expressed in essentially all human tumors. In fact, heparanase 
over-expression correlates with poor prognosis in a variety of cancers [18, 19].  
We have previously shown that heparin analogues obtained from marine invertebrate 
bind to P-selectin, attenuating metastasis, inflammation and thrombosis [20, 21]. In a recent 
study, we described a unique heparan sulfate (HS) isolated from the bivalve mollusk 
Nodipecten nodosus. This sulfated polysaccharide is formed by glucuronic acid and 
glucosamine and can also contain a rare pattern of sulfation on carbon 2 and 3 of the 
glucuronic acid units. We also described that this compound was able to inhibit thrombus 
growth without inducing bleeding effect [22]. 
 Although increasing evidence points to a beneficial therapeutic action of heparin in 
cancer patients, its bleeding effect still limits its use. Here, we addressed the ability of HS 
from N. nodosus to attenuate leukocyte recruitment and cancer metastasis. Our results reveal  
that the mollusk HS presents effective P-selectin inhibitory activity, decreasing the binding of 
carcinoma cells to P-selectin in vitro and its interaction with platelets in vivo. The mollusk 
glycan also inhibits heparanase enzymatic activity in vitro. Moreover, we have demonstrated 
that this glycan attenuates hematogenous metastasis and polymorphonuclear cells recruitment 
in vivo.  
 
Materials and methods 
 
Cell lines and reagents 
Human colon carcinoma cells (LS180; ATCC, Manassas, VA, USA) were grown in 
minimum essential medium-α (MEM-α) (Invitrogen,Carlsbad, CA, USA) supplemented with 
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10% fetal bovine serum (FBS) (Invitrogen). Mouse Lewis lung carcinoma cells (LLC) were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) (Vitrocell)  supplemented with 
10% FBS. All reagents were from Sigma (St Louis, MO, USA) unless otherwise stated. UFH 
(Liquemine) was obtained from RochePharma (Reinach, Switzerland).  
 
Isolation of HS from N. nodosus  
 Adult specimens of the bivalve mollusk Nodipecten nodosus (Linnaeus, 1778) were 
collected from Baia da Ilha Grande, Angra dos Reis, Rio de Janeiro, Brazil. The 
polysaccharides were extracted by protease digestion and purification as described previously 
[22]. 
Inhibition of tumor cell binding to immobilized p-selectin 
The ability of glycosaminoglycans to inhibit the adhesion of calcein AM-labeled LS180 cells 
to immobilized P-selectin chimeras was performed as described previously [23]. Each glycan 
was tested in triplicate wells at each concentration. 
Intravital microscopy 
Leukocyte rolling in the mesenteric venules was analyzed after 4 hours of lipopolysaccharide 
(LPS) (Sigma; 0,5mg/kg) or PBS intravenous injection. Adult male and female Wistar rats 
(250 g body weight) were anesthetized with an intramuscular injection of 100 mg kg-1 of 
ketamine (Cristália, São Paulo, Brazil) and 16 mg kg-1 of xylazine (Bayer AS, São Paulo, 
Brazil). An abdominal midline incision (around 1,5 cm) was performed and the mesentery 
was exposed for analysis. After positioning under the microscope, a 30 min equilibration 
period preceded quantitative measurements. The microscopy used was Zeiss Axio ImagerA1. 
Leukocyte rolling was counted for 10 min. In the group that received LPS, leukocyte rolling 
was evaluated before and after circulation of N. nodosus HS for 5 min (2mg/kg - intravenous 
injection). Videos are available at supplemental material. 
 
 
Thioglycollate-induced peritoneal inflammation  
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 Mice were injected intraperitonealy with 4% thioglycollate (1mL). After 5 min, N. 
nodosus HS was administrated via tail vein injection. Mice were sacrificed after 3 hours and 
peritoneal lavage was collected using 4 mL ice-cold PBS, containing 3 mM EDTA to prevent 
clotting. The peritoneal fluid, 200 µL, was analyzed after cytospin preparation by 
hematoxylin and eosin staining. Then, differential counting was performed to evaluate the 
amount of polymorphonuclear cells present in the peritoneal cavity. P-selectin-deficient mice 
(P-sel -/-) and wild type mice were used in this experiment. 
Tumor cell-platelets association in vivo 
The formation of tumor cell-platelet complex was performed as described before [9]. Briefly, 
LLC cells were harvested with 2 mM EDTA in phosphate-buffered saline (PBS), labeled with 
calcein AM, and injected intravenously into mice with or without previous intravenous 
application of 200 µg of N.nodosus HS . 30 min later lungs were harvested for analysis. Lung 
sections were stained with goat anti-integrin αIIb (CD41) (Santa Cruz biotechnology-
sc6602), followed by anti-goat Cy3-conjugated antibody (Sigma), and analyzed by 
immunofluorescence microscopy. The extent of platelet association with tumor cells was 
quantified by evaluating calcein-labeled cells present in 40 fields of lung sections. 
 
Heparanase enzymatic activity assay 
 
Preparation of sulfate-labeled extracellular matrix (ECM)–coated dishes and determination of 
heparanase enzymatic activity were performed as previously described [24, 25].  Briefly, 
sulfate-labeled ECM coating the surface of 35-mm culture dishes was incubated (4 hours, 
37°C, pH 6.0) with constitutively active  recombinant human heparanase (120 ng/ml) in the 
absence or presence of 5 μg/ml of mollusk HS, as described [18]. The incubation medium 
containing sulfate-labeled degradation fragments was subjected to gel filtration on a 
Sepharose CL-6B column. Fractions (0.2 ml) were eluted with PBS and their radioactivity 
counted in a β-scintillation counter. HS degradation fragments were eluted at 0.5 < Kav < 0.8 
(peak II, fractions 10–25). 
 
 
 
Experimental metastasis model 
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Mice (8 - 10 weeks old) were intravenously injected with 106 LLC cells via the tail vein. N. 
nodosus HS or PBS administration was performed 10 min prior to cell injection. Mice were 
sacrificed after 21 days. The lungs were macroscopically evaluated for the number of 
metastatic foci. 
Results 
HS from N.nodosus attenuates tumor cell binding to P-selectin 
 Because P-selectin is a crucial mediator of cell-cell interactions during inflammation 
and cancer, we evaluated whether HS from N.nodosus could inhibit P-selectin. For this 
purpose, we analyzed the ability of this compound to impair adhesion of LS180 cells to 
immobilized P-selectin. It is known from previous work that this colon cancer cell line 
express high content of selectin ligands [26]. N.nodosus HS decreased tumor cell binding to 
P-selectin in a dose dependent manner, yielding an IC50 of 38,19 µg/mL, comparable to that 
of unfractionated heparin from porcine intestine (UFH) (IC50 of 24,51 µg/mL)  (Figure 2).  It 
is worth pointing that because UFH presents lower molecular weight (around 15 kDa) than 
HS from N.nodosus (around 30 kDa), the molar concentration of UFH is higher than that of 
HS from N.nodosus. 
HS from N.nodosus reduces leukocyte rolling and cell recruitment after inflammatory 
stimulus 
 While the involvement of inflammatory cells during several steps of cancer 
progression is well documented, little is known about the underlying mechanism. Because 
leukocyte rolling on activated endothelium during inflammatory response is mediated by P-
selectin we investigated how leukocyte rolling is affected by N.nodosus HS treatment. 
Previous studies have shown that LPS treatment induces P-selectin upregulation in 
endothelial cells [27]. Based on this, we analyzed leukocyte rolling on LPS-activated 
endothelium before and after N.nodosus HS administration, applying intravital microscopy. It 
was observed that N.nododus HS treatment inhibited LPS-induced leukocyte rolling to the 
basal level (Fig. 3, A). Because leukocyte rolling is the first step for cell recruitment, we 
further evaluated the effect N. nodosus HS on a thioglycollate-induced peritonitis model in 
mice. After 3 hours of inflammatory stimulus, the peritoneal lavage was harvested and 
differential counting of leukocytes was performed. Figure 3B shows that thioglycollate 
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promoted a significant increase in the recruitment of polymorphonuclear cells to the 
peritoneal cavity, compared to control. N. nodosus HS treatment resulted in a 70% reduction 
in leukocyte recruitment. This effect was similar to observed reduction of leukocyte 
recruitment in untreated P-selectin-deficient mice (P-sel-/-). Interestingly, treatment of P-sel-/- 
mice with HS from N. nodosus led to a lower leukocyte recruitment in comparison to both 
HS-treated wild-type or untreated P-sel-/- mice (Figure 3C). These findings suggest an 
additional mechanism involved in the inhibition of leukocyte recruitment by N. nodosus HS 
besides P-selectin. Considering that previous studies have shown that some 
glycosaminoglycans also inhibit L-selectin [21], we suggest that this glycan may additionally 
be blocking L-selectin. 
N. nodosus HS inhibits association between tumor cells and platelets in vivo 
 As mentioned before, P-selectin dependent leukocyte recruitment and intercellular 
interactions are crucial during inflammation and tumor metastasis as well. P-selectin- 
mediated platelet association with tumor cells contributes to the accomplishment of 
metastasis. In previous studies, we showed that glycosaminoglycans from marine 
invertebrates could disrupt this association. In order to analyze the ability of HS from N. 
nodosus to inhibit tumor cell-platelet interactions in vivo, HS (200 µg/mouse) was injected 
via tail vein 5-10 min before injection of LLC cells. Lungs were analyzed by 
immunofluorescence 30 min after tumor cell (calcein labelled) injection. While in the control 
group, approximately 70% of tumor cells were associated with platelets (Fig. 4), N. nodosus 
HS administration significantly reduced tumor cell-platelet association to 30%. 
Mollusk HS inhibits heparanase and attenuates experimental metastasis 
 LLC cells express high amounts of heparanase [28], which plays a relevant role in 
tumor invasion and metastasis [29]. Because heparanase has been pointed as a molecular 
target of heparin in cancer, we wondered whether HS from N. nodosus inhibits heparanase 
enzymatic activity, possibly affecting tumor invasion. For this purpose, we used a naturally 
produced sulfate-labeled ECM as substrate and measured the release of HS degradation 
fragments upon incubation with heparanase [24, 25]. As demonstrated in Figure 5, the 
mollusk HS inhibited heparanase enzymatic activity. Because metastasis efficiency depends 
on P-selectin and heparanase, and UFH treatment is known to decrease tumor metastasis, we 
sought to assess the anti-metastatic activity of N. nodosus HS [6, 9].  In order to investigate 
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this, we applied an experimental metastasis model in mice, using Lewis lung carcinoma 
(LLC) cells that express P-selectin ligands and heparanase. This experiment involved 
administration of 200 µg N. nodosus HS followed by injection (tail vein) of LLC carcinoma 
cells. Figure 6 shows the effect of the mollusk HS treatment on metastasis. Whereas the 
number of metastatic foci was high in control lungs, HS-treated animals presented just few 
metastatic foci. We also noticed that the tumor burden in control lungs was higher than in the 
treated animals.  Overall, these results indicate that the mollusk HS may be an attractive 
therapeutic drug to block both P-selectin-mediated interactions and heparanase activity, 
blunting metastasis and inflammation without inducing bleeding effects. 
  
Discussion 
 Cell interactions among leukocytes, platelets and endothelium are mediated by 
selectins and contribute to the pathophysiology of inflammation and metastasis.  Several 
studies have shown that heparin can block these interactions and therefore attenuate 
hematogenous metastasis and inflammatory cell recruitment. In 2010, we described a unique 
heparan sulfate obtained from the bivalve mollusk  Nodipecten nodosus, which presents 2 or 
3 O-sulfation on glucuronic acid (Fig. 1). This compound is extracted from organs commonly 
discarded during preparation for commercialization and presents anti-thrombotic activity 
without inducing any bleeding effect [22]. Therefore, we thought to investigate if this glycan 
could be a useful p-selectin inhibitor.  In order to evaluate this inhibitory potential we 
performed in vitro and in vivo experiments and showed that the mollusk HS inhibits p-
selectin interaction with colon carcinoma cell line (LS180), decreases cell rolling and 
inflammatory cell recruitment. Additionally it attenuates platelets-tumor cell association and 
heparanase enzymatic activity, thereby blunting metastasis of Lewis lung carcinoma cells 
(LLC). 
 Leukocyte function in tumor biology has deserved attention in cancer research [30, 
31]. It has been proposed that, in some types of cancer, the inflammatory cascade is already 
activated before the tumor initiates [3]. Conversely, in other situations the malignant 
microenvironment promotes inflammatory cells recruitment, which in turn can induce tumor 
growth [32, 33] or lysis of tumor cells. Inflammatory leukocyte rolling on activated 
endothelium is a p-selectin mediated event. Applying intravital microscopy, we showed  that 
mollusk HS decreases leukocyte rolling after endothelial cell activation (Fig. 3A). We 
speculate that as a consequence of this inhibition polymorphonuclear cells recruitment to the 
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peritoneal cavity was attenuated as well (Fig.3B).  We also observed a decrease in leukocyte 
recruitment in p-selectin deficient mice (Fig.3C). As some glycosaminoglycans also bind to 
L-selectin, inhibition of leukocyte recruitment through L-selectin interaction can be expected, 
as well. Therefore we suggest that HS from N. nodosus might also inhibit L-selectin. 
 Another branch of p-selectin-mediated interactions occurs during dissemination of 
metastatic cancer cells. Along this process after bloodstream entry, tumor cells are often 
covered with platelets in a p-selectin dependent manner. This interaction confers the tumor 
cells with physical shielding mediated by platelets, avoiding natural killer cell mediated 
tumor cell lysis. We found that the mollusk glycan inhibited significantly tumor-cell platelet 
association, already 30 min after tumor cells injection (Fig. 5).  We suggest that without 
this interaction tumor cells would be more vulnerable to immune surveillance and as a result 
the metastasis rate would decrease. Using LLC cells, which are carcinoma cells that express 
selectin ligands at the cell surface [34], we demonstrated that the mollusk glycan drastically 
attenuates seeding of tumor cells to the lungs. An elegant work of Labelle et al (2011) 
showed that apart of protection from leukocytes, platelets can induce epithelial-mesenchymal 
transition in tumor cells via TGFβ mediated-mechanism and thereby promote metastasis. 
Similarly, through inhibition of platelet-tumor cell interaction the mollusk glycan may exert 
anti-metastatic effect by suppressing the epithelial mesenchymal transition induced by 
platelets. 
  When tumor cells exit the bloodstream they need to degrade the sub-endothelial 
basement membrane, which is rich in heparan sulfate, in order to colonize a secondary site 
[35].  Previous studies have shown that heparin-mimicking compounds attenuate metastasis 
by acting as heparanase inhibitors as well [36]. Therefore we suggest that the heparanase 
inhibitory activity of the mollusk  glycan contributes to the anti-metastatic effect observed in 
our experiments.   
 Overall, the present work identifies a new p-selectin inhibitor that does not induce 
hemorrhagic effects observed in mammalian heparin. We also showed that this compound 
attenuates thrombosis, inflammation and metastasis. Since cancer disease is usually 
associated with thrombotic events we suggest that the mollusk HS is an attractive candidate 
to be a therapeutic drug for cancer-associated thrombosis and cancer-related inflammation.  
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Figure Legends 
Figure 1. Structure of HS from N. nodosus. The residues denoted with G and A are 
glucoronate and D-glucosamine, respectively. 
Figure 2. HS from N.nodosus attenuates p-selectin binding to LS180 tumor cells. LS-180 
human colon carcinoma cells adhesion to immobilized P-selectin chimera was measured in 
the presence of increasing concentrations of HS from N. nodosus (open circles) or 
unfractionated heparin (filled squares). The curves are representative of three independent 
experiments.  See “Material and methods” for experimental details. 
Figure 3. HS from N. nodusus inhibitis leukocyte rolling and polymorphonuclear cell 
recruitment. (A) Leukocyte rolling (cells/min) along the endothelium of post-capillary 
venules in distal ileum was measured by use of intravital microscopy. Four hours before 
counting, rats were intravenously injected with LPS (0,5 mg/Kg) or saline. In rats treated 
with LPS the leukocyte rolling was measured before and after intravenous administration of 
HS from N. nodusus (2 mg/Kg). (B-C) Thioglycolate was injected intraperitonealy, followed 
by intravenous injection of mollusk HS (0.5 mg/mouse) 5 minutes later. Peritoneal lavage 
was harvested 3 hours later. Cells were stained with hematoxylin and eosin and differentially 
counted for mononuclear and polymorphonuclear cells. (B) wild- type mice. (C) P-selectin 
knockout mice. Arrows indicate polymorphonuclear cells. Scale Bar represents 20 µm. The 
statistical significance was determined by one-way ANOVA (*** p< 0.001). 
Figure 4. HS from N. nodosus inhibits platelet adhesion to tumor cell in vivo.  LLC cells 
labeled with calcein AM were intravenously injected via tail vein. (A) Representative images 
of platelet-tumor cell association in lungs of mice injected with either HS from N.nodosus 
(200µg) or PBS euthanized 30 min later. Scale bar represent 20 µm; (B) Numbers of platelet–
tumor cell aggregates are presented as percentages (in columns) of all counted tumor cells. 
The statistical significance of tumor cell–platelet association was determined by Test-T (*** 
p< 0.001). 
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Figure 5. HS from N. nodosus is a heparanase inhibitor. The ability of mollusk HS to 
inhibit recombinant heparanase enzymatic activity was determined as described in Materials 
and Methods. Data are representative of three independent experiments. 
Figure 6. Experimental lung metastasis of LLC carcinoma cells is attenuated by mollusk 
HS treatment. Mice were intravenously injected with 200 μg of mollusk HS, 10 minutes 
before injection of 106 LLC cells and killed 21 days later. Metastatic foci in the lungs were 
evaluated macroscopically. (A) Representative images of lungs harvested from mice injected 
with mollusk HS versus control. (B) Counting of metastatic foci. 
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